Market Intelligence, Clinical Progress, and High-Purity Reagents for Metabolic and Cholestatic Liver Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PPARD drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (LBD) | PPARD Ligand Binding Domain Recombinant Protein High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. E. coli / HEK293 Expressed. |
View PPARD Products |
| Antigen (Full-Length) | PPARD Full-Length Recombinant Protein High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 Expressed. |
View PPARD Products |
| Mutant Panel | PPARD Mutant Variants (Selectivity Screen) Sequence Verified for PPAR subtype discrimination assays. |
View PPARD Products |
| Gene Delivery | PPARD Promise-ORF / Lentivirus Full-length ORF for stable cell lines and reporter assays. |
View PPARD Products |
| Benchmark Ab | Anti-PPARD Recombinant Antibody Sequence Verified. Suitable for Western blot, ChIP, ICC. |
View PPARD Products |
| Validator | PPARD siRNA Set For knockdown verification and specificity controls in cell-based assays. |
View PPARD Products |
| Related Target A | PPARA Essential for selectivity counterscreening (Dual vs. Selective agonists). |
View PPARA Products |
| Related Target B | PPARG Crucial anti-target for PPARD-selective drugs to avoid adipogenic side effects. |
View PPARG Products |
| Related Target C | RXRA Obligate heterodimer partner for PPARD transcriptional activity. |
View RXRA Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily Counter Screening (PPARA/G/D) | Homolog panel proteins (PPARA, PPARD, PPARG) strictly verified by mass spec with >95% purity for TR-FRET/SPR. |
| Ligand Binding & Coactivator Recruitment | PPARD LBD produced with native folding; Endotoxin <1 EU/µg; compatible with TR-FRET/AlphaScreen. |
| Functional Cellular Assays | High-titer Lentivirus available for building stable nuclear receptor reporter cell lines. |
| Cross-species Preclinical Evaluation | Human, Mouse, and Cynomolgus PPARD ortholog proteins with strict sequence alignment. |
| Safety Profiling (Off-target liability) | Mutant variant panel available for binding site characterization and selectivity optimization. |
| Lack of Reliable Controls / False Positives | Sequence-verified recombinant proteins, antibodies, and siRNA for consistent lot-to-lot benchmarking. |
Live PPARD R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PPARD therapeutics is maturing, with major players driving advanced clinical trials in rare liver and metabolic disorders. Small molecule agonists remain the dominant modality. First-generation therapies such as seladelpar (CymaBay/Gilead) have gained regulatory traction in Primary Biliary Cholangitis (PBC), validating the target in cholestatic disease. The next wave of R&D is targeting broader indications like Metabolic dysfunction-associated steatohepatitis (MASH), dyslipidemia, and severe muscle dystrophies. Strategic focus is shifting from pan-PPAR agonists to highly selective PPARD modulators (SPPARMs) with improved safety margins, tissue-specific distribution, and partial agonist mechanisms to mitigate preclinical carcinogenicity signals (e.g., GW501516 legacy). Emerging approaches include local topical formulations for wound healing and PROTAC degraders for oncology applications.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Selective PPARδ Agonist | CymaBay/Gilead (Seladelpar), Reneo, Kestrel Therapeutics | PBC, Primary Mitochondrial Myopathies, NASH, Fibrosis | Subtype Selectivity Assay (Need PPARα/γ/δ protein trio) |
| Dual PPARα/δ Agonist | Genfit/Ipsen (Elafibranor) | PBC, NASH (discontinued in NASH) | Dual Counter-Screen (Need PPARA + PPARD co-activity reagents) |
| Pan-PPAR Agonist | Inventiva (Lanifibranor) | MASH/NASH | Broad Selectivity Profiling (Full PPAR family protein panel) |
| Topical Formulation | Derm-focused Biotechs | Wound Healing, Dermatitis | Tissue Permeability Models (Need high-concentration protein standards) |
| PROTAC/Degrader | Emerging Academic/Startup consortia | Oncology (Emerging) | Full-length Protein Integrity (Need ORF/Lentivirus for cellular assays) |
| Gene Therapy / RNAi | Emerging Biotechs | Metabolic Syndrome | Target Knockdown Validation (Need sequence-verified siRNA) |
Key Differentiators for Best-in-Class Agents
To achieve best-in-class status, PPARD modulators must excel in:
- Subfamily Selectivity: >100-fold selectivity over PPARG to avoid adipogenic side effects, and over PPARA to avoid liver toxicity. High-purity homolog panels from TarMart enable robust selectivity profiling.
- Coactivator Recruitment Profile: Differential engagement of SRC-1, PGC-1α, and other coactivators drives therapeutic specificity. TR-FRET assays with TarMart LBD proteins allow precise coactivator fingerprinting.
- Safety & Tolerability: Partial agonism or tissue-specific distribution can reduce carcinogenicity risk. Mutant panels and cross-species orthologs support early safety de-risking.
- Functional Validation: Lentivirus-based stable reporter cell lines confirm cellular penetration and transactivation efficacy. Coupled with siRNA knockdown, false positives are minimized.
Related Targets for Combination & Cross-Selling
- PPARA (View PPARA Products) & PPARG (View PPARG Products): Essential for selectivity counter-screening and dual/pan-PPAR development.
- RXRA (View RXRA Products): Obligate heterodimer partner; needed for functional assays and cofactor recruitment studies.
- FXR (NR1H4) (View FXR Products): Key bile acid receptor frequently co-targeted in PBC/MASH regimens; offers parallel mechanism evaluation.